Increased synthesis of indoleamine-2,3-dioxygenaseprotein is positively associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer

Oncology Reports

Volumn 17, Issue 6, 2007, Pages 1333-1339

  Takao, Miho ^a   Okamoto, Aikou ^a   Nikaido, Takashi ^a   Urashima, Mitsuyoshi ^a   Takakura, Satoshi ^a   Saito, Misato ^a   Saito, Motoaki ^a   Okamoto, Sanshiro ^a   Takikawa, Osamu ^b   Sasaki, Hiroshi ^a   Yasuda, Makoto ^a   Ochiai, Kazunori ^a   Tanaka, Tadao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

Author keywords

Endometriosis; Immunohistochemistry; Indoleamine 2,3 dioxygenase; Ovarian cancer; Paclitaxel; Serous adenocarcinoma

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; TUMOR MARKER;

ARTICLE; CYSTADENOCARCINOMA; ENZYMOLOGY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MORTALITY; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; UPREGULATION;

CYSTADENOCARCINOMA, SEROUS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 34548024195     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.17.6.1333     Document Type: Article

References (30)

1. Lister-Sharp D, McDonagh MS, Khan KS and Kleijnen J: A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer. Health Technol Assess 4: 1-113, 2000.
2. Okamoto A, Nikaido T, Ochiai K, et al: Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells. Clin Cancer Res 11: 6030-6039, 2005. (Pubitemid 41170335)
3. Uyttenhove C, Pilotte L, Theate I, et al: Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9: 1269-1274, 2003. (Pubitemid 37279849)
4. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E and Prendergast GC: Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 11: 312-319, 2005. (Pubitemid 40460560)
5. Ono K, Tanaka T, Tsunoda T, et al: Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res 60: 5007-5011, 2000.
6. Enomoto T, Weghorst CM, Inoue M, Tanizawa O and Rice JM: K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary. Am J Pathol 139: 777-785, 1991.
7. Fujita M, Enomoto T, Inoue M, et al: Alteration of the p53 tumor suppressor gene occurs independently of K-ras activation and more frequently in serous adenocarcinomas than in other common epithelial tumors of the human ovary. Jpn J Cancer Res 85: 1247-1256, 1994.
8. Ichikawa Y, Nishida M, Suzuki H, et al: Mutation of K-ras protooncogene is associated with histological subtypes in human mucinous ovarian tumors. Cancer Res 54: 33-35, 1994. (Pubitemid 24042083)
9. Pieretti M, Cavalieri C, Conway PS, Gallion HH, Powell DE and Turker MS: Genetic alterations distinguish different types of ovarian tumors. Int J Cancer 64: 434-440, 1995. (Pubitemid 26048908)
10. Teneriello MG, Ebina M, Linnoila RI, et al: p53 and Ki-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 53: 3103-3108, 1993. (Pubitemid 23210320)
11. Dent J, Hall GD, Wilkinson N, et al: Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation. Br J Cancer 88: 1578-1583, 2003. (Pubitemid 36713785)
12. Enomoto T, Kuragaki C, Yamasaki M, et al: Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin? Proc Am Soc Clin Oncol 22: 447, 2003.
13. Clark TG, Stewart ME, Altman DG, Gabra H and Smyth JF: A prognostic model for ovarian cancer. Br J Cancer 85: 944-952, 2001. (Pubitemid 33015994)
14. Sugiyama T, Kamura T, Kigawa J, et al: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 88: 2584-2589, 2000. (Pubitemid 30331967)
15. Goff BA, Sainz de la Cuesta R, Muntz HG, et al: Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. Gynecol Oncol 60: 412-417, 1996.
16. Schwartz DR, Kardia SL, Shedden KA, et al: Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res 62: 4722-4729, 2002.
17. Tsuda H, Ito YM, Ohashi Y, et al: Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res 11: 6880-6888, 2005. (Pubitemid 41428744)
18. Stern RC, Dash R, Bentley RC, Snyder MJ, Haney AF and Robboy SJ: Malignancy in endometriosis: frequency and comparison of ovarian and extraovarian types. Int J Gynecol Pathol 20: 133-139, 2001. (Pubitemid 32239204)
19. Sekizawa A, Amemiya S, Otsuka J, et al: Malignant transformation of endometriosis: application of laser microdissection for analysis of genetic alterations according to pathological changes. Med Electron Microsc 37: 97-100, 2004. (Pubitemid 38980910)
20. Kato N, Sasou S and Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol 19: 83-89, 2006. (Pubitemid 43250982)
21. Munn DH, Sharma MD, Lee JR, et al: Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 297: 1867-1870, 2002. (Pubitemid 35024345)
22. Friberg M, Jennings R, Alsarraj M, et al: Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101: 151-155, 2002. (Pubitemid 34970907)
23. Munn DH, Sharma MD, Hou D, et al: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114: 280-290, 2004. (Pubitemid 39071633)
24. Bai F, Feng J, Cheng Y, Shi J, Yang R and Cui H: Analysis of gene expression patterns of ovarian cancer cell lines with different metastatic potentials. Int J Gynecol Cancer 16: 202-209, 2006.
25. Lancaster JM, Dressman HK, Clarke JP, et al: Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 16: 1733-1745, 2006. (Pubitemid 44470029)
26. Takei Y, Mizukami H, Saga Y, et al: Overexpression of a hybrid gene consisting of the amino-terminal fragment of urokinase and carboxyl-terminal domain of bikunin suppresses invasion and migration of human ovarian cancer cells in vitro. Int J Cancer 113: 54-58, 2005. (Pubitemid 39507310)
27. Luo LY, Katsaros D, Scorilas A, et al: The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res 63: 807-811, 2003. (Pubitemid 36231980)
28. Luo LY, Katsaros D, Scorilas A, et al: Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res 7: 2372-2379, 2001.
29. Takano M, Fujii K, Kita T, Kikuchi Y and Uchida K: Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer. Oncol Rep 12: 1177-1182, 2004.
30. Matsuzaki H, Kobayashi H, Yagyu T, et al: Plasma bikunin as a favorable prognostic factor in ovarian cancer. J Clin Oncol 23: 1463-1472, 2005.